Leukotriene antagonists and inhibitors: clinical applications.
Ford-Hutchinson
A W
AW
Merck Frosst Centre For Therapeutic Research, Pointe Claire (Dorval), Quebec, Canada.
D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006918:Hydroxyurea / Q000031:analogs & derivatives / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000503:physiopathology; D020024:Leukotriene Antagonists; D015289:Leukotrienes / Q000502:physiology; D008565:Membrane Proteins; D011422:Propionates / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy* / Q000503:physiopathology; D011804:Quinolines / Q000627:therapeutic use; D018077:Receptors, Leukotriene; D002722:Chlorobenzenes
D006918:Hydroxyurea; D007211:Indoles; D020024:Leukotriene Antagonists; D015289:Leukotrienes; D008565:Membrane Proteins; D011422:Propionates; D011804:Quinolines; D018077:Receptors, Leukotriene; C060893:MK-886; D002722:Chlorobenzenes; C059141:verlukast; C412375:cysteinyl leukotriene receptor 2; C083169:leukotriene D4 receptor; C063449:zileuton